Allergy Immunotherapy Market Research Report By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies), By Patient Type (Pediatric, Adult, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Global Allergy Immunotherapy Market Overview

As per MRFR analysis, the Allergy Immunotherapy Market Size was estimated at 5.32 (USD Billion) in 2023.The Allergy Immunotherapy Market Industry is expected to grow from 5.71(USD Billion) in 2024 to 12.5 (USD Billion) by 2035. The Allergy Immunotherapy Market CAGR (growth rate) is expected to be around 7.38% during the forecast period (2025 - 2035)

Key Allergy Immunotherapy Market Trends Highlighted

The Allergy Immunotherapy Market is growing a lot because more and more people are getting allergic disorders, including asthma, allergic rhinitis, and food allergies. The market is rising because more people are learning about immunotherapy as a treatment option, and more people want ways to control their allergies. More and more people are choosing personalised treatment programs that include injectable immunotherapy and sublingual pills, which have been found to help with symptoms. There are several chances in this sector, especially as technology improves delivery methods and formulas.

People are paying more attention to new ideas like smart gadgets that help track allergy therapy. There is also a growing trend towards developing new products that concentrate on patient comfort and compliance. In allergy immunotherapy, statistics suggest that biologics are becoming more common. Biologic medicines are getting more and more regulatory approvals in different parts of the world because they may help control severe allergic reactions. Global health authorities also stress the need for better allergy management as part of public health efforts, which encourages more money to be spent on allergy research and development. Another important development is the rise of online platforms that provide information and resources on allergy immunotherapy. This makes it simpler for patients to find out more and get treatments.

This change to digital might help patients become more involved and stick to their treatment plans. As more people learn about allergies and more treatment choices become available, it is expected that the worldwide market will adopt a more proactive approach to managing allergies. This is a big opportunity for stakeholders to provide complete care solutions.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Allergy Immunotherapy Market Drivers

Increasing Prevalence of Allergies

The Allergy Immunotherapy Market Industry is significantly driven by the rising prevalence of allergies, which has been a growing concern worldwide. According to the World Health Organization, allergies are now affecting over 30% of the global population, with rates continuing to rise annually by approximately 5%. This alarming trend indicates a heightened demand for effective treatment options, including allergy immunotherapy. In countries like the United States, the Centers for Disease Control and Prevention report that more than 50 million people experience various types of allergies each year.

This increasing incidence provides a robust market opportunity for immunotherapy solutions to alleviate the growing burden of allergic diseases, thereby enhancing the growth prospects of the Allergy Immunotherapy Market Industry.

Advancements in Immunotherapy Techniques

The Allergy Immunotherapy Market Industry is witnessing significant advancements in immunotherapy techniques, which contributes to the market's growth. Innovations in sublingual and injectable immunotherapy approaches are becoming more widespread, allowing for better patient compliance and effectiveness. Research funded by organizations such as the National Institutes of Health has shown that these modern techniques improve treatment outcomes by up to 60% in cases of allergic rhinitis and asthma.

These advancements make treatments more accessible and effective, thus expanding the patient base and fueling the growth of the Allergy Immunotherapy Market Industry.

Increasing Consumer Awareness and Education

Consumer awareness regarding allergies and available treatment options is on the rise, significantly impacting the Allergy Immunotherapy Market Industry. Public health campaigns initiated by organizations like the Allergy and Asthma Foundation have led to an increase in knowledge among the population about allergies and the role of immunotherapy in treatment. Surveys indicate that up to 70% of individuals suffering from allergies are now aware of immunotherapy as an effective treatment option.

This heightened awareness translates to increased demand for immunotherapy services, propelling the growth potential of the Allergy Immunotherapy Market Industry.

Growing Healthcare Expenditure

Increased healthcare expenditure globally is a crucial driver for the Allergy Immunotherapy Market Industry. According to the World Bank, global healthcare expenditure has increased by about 10% over the past five years, reaching a staggering USD 7.8 trillion in 2022. This rise reflects an expanding focus on improving overall health outcomes, including investing in allergy management. 

As healthcare spending rises, more resources are allocated towards innovative treatments like allergy immunotherapy, which can help alleviate the long-term costs associated with chronic allergic reactions.This trend creates a favorable environment for the expansion of the Allergy Immunotherapy Market Industry.

Allergy Immunotherapy Market Segment Insights

Allergy Immunotherapy Market Type Insights

The Allergy Immunotherapy Market is experiencing noteworthy growth, driven by increasing awareness of allergy management and the demand for effective treatment options. In 2024, the market is set to attain a value of 5.71 USD Billion, showcasing its significance in the healthcare landscape. This segment is intricately divided into three main areas: Subcutaneous Immunotherapy, Sublingual Immunotherapy, and Oral Immunotherapy, each contributing to the overall market in distinct ways. Notably, Subcutaneous Immunotherapy is expected to dominate this market segment significantly, with a valuation of 2.5 USD Billion in 2024, growing to 5.5 USD Billion by 2035.

This treatment type is recognized for its effectiveness in eliciting immune response through targeted injections, making it a preferred choice for many patients. Following closely behind, Sublingual Immunotherapy is projected to be valued at 1.8 USD Billion in 2024 and expand to 4.0 USD Billion by 2035. Its sublingual administration presents a convenient alternative for patients who may be apprehensive about injections, thus gaining traction in recent years. Meanwhile, Oral Immunotherapy, which holds a valuation of 1.41 USD Billion in 2024 and is poised to reach 3.0 USD Billion in 2035, provides an innovative approach by introducing allergens through oral intake, resonating well with those seeking less invasive options.

The combined growth of these therapies reflects a broader change in how allergies are perceived and treated, with an increased focus on personalized medicine and patient comfort. As the Allergy Immunotherapy Market evolves, these treatment types are positioned to address specific patient preferences, enhancing adherence and overall treatment outcomes. Furthermore, ongoing research and advancements in allergen extraction techniques and immunological understanding are likely to fuel new opportunities within these therapeutic areas, driving up market statistics and enriched patient experiences.

This growth is further supported by rising incidences of allergic conditions worldwide, emphasizing the necessity for effective immunotherapy solutions that cater to diverse preferences within the patient population. Overall, the segmentation of the Allergy Immunotherapy Market illustrates a dynamic landscape that continues to adapt in response to the needs and demands of consumers, highlighting the importance of these treatment modalities in managing allergies on a global scale.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Allergy Immunotherapy Market Product Insights

The Allergy Immunotherapy Market is poised for significant growth, with a valuation of 5.71 billion USD in 2024 and a projected increase to 12.5 billion USD by 2035. Within the Product segmentation, Allergen Extracts significantly influence market dynamics, serving as fundamental components in allergy treatments. Conventional Immunotherapy continues to be a prevalent choice due to its established efficacy in managing allergic reactions, hence holding a significant market share. Biologics also represent a critical aspect of the market, offering innovative approaches to allergy management, particularly for patients who do not respond to traditional treatments.

As the population experiences an increase in allergic conditions globally, there is an escalating demand for effective immunotherapy products, driving research and development efforts. The integration of advanced technologies and heightened awareness around allergies will further foster growth opportunities within the Allergy Immunotherapy Market, enhancing both product offerings and patient outcomes.

Allergy Immunotherapy Market Indication Insights

The Allergy Immunotherapy Market emphasizes various indications such as Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies, which are critical areas driving the market's growth and development. In 2024, the market is expected to reach a valuation of approximately 5.71 USD Billion, signaling robust consumer demand and increasing awareness regarding allergy treatments. Allergic Rhinitis continues to dominate as the leading indication, largely due to its pervasive nature among children and adults globally. Allergic Asthma and Atopic Dermatitis also hold significant positions in the market, reflecting the need for effective management strategies which enhance the quality of life for millions.

Food Allergies, increasingly recognized for their impact, are emerging as crucial in the immunotherapy landscape, leading to a rise in targeted therapies. The growing prevalence of these conditions aligns with increasing healthcare expenditure and advancements in treatment technologies, which are propelling the Allergy Immunotherapy Market forward. The market faces challenges such as treatment accessibility and varying regulations across regions, yet ongoing Research and Development efforts provide promising opportunities to innovate and expand treatment offerings within these indications.

Allergy Immunotherapy Market Patient Type Insights

The Allergy Immunotherapy Market is significantly driven by the diverse Patient Type segment, which includes Pediatric, Adult, and Geriatric classifications. This division highlights the unique needs and treatment responses across different age groups, influencing the overall market dynamics. In 2024, the Allergy Immunotherapy Market is expected to reach a valuation of 5.71 USD Billion, reflecting a growing demand for specialized treatments tailored to each patient category. The Pediatric segment is especially noteworthy, as early intervention can drastically improve life quality and decrease long-term allergy-related complications.

Adults constitute a predominant share of the market due to their higher exposure to allergens in daily life and the increasing prevalence of allergies in urban settings. The Geriatric population is also gaining significant attention, driven by chronic conditions that often exacerbate allergies and the need for effective management strategies. Overall, as the Allergy Immunotherapy Market evolves, understanding these Patient Types will be crucial for developing targeted therapies and optimizing treatment outcomes, thereby aligning with broader health objectives globally.

Allergy Immunotherapy Market Regional Insights

The Allergy Immunotherapy Market is witnessing significant growth across its regional segmentation. In 2024, North America leads the market with a valuation of 2.35 USD Billion, driven by high prevalence rates of allergies and advanced healthcare infrastructure. Europe follows with a substantial valuation of 1.7 USD Billion, fueled by an increasing awareness of allergic conditions and improved diagnostic techniques. South America, with a market value of 0.4 USD Billion, holds potential due to rising healthcare access in developing countries, while Asia Pacific is valued at 0.9 USD Billion, highlighting the growing demand for allergen-specific treatments in densely populated regions.

The Middle East and Africa represent a smaller segment valued at 0.36 USD Billion, yet are emerging markets with increasing focus on allergy treatments. Each region significantly contributes to the Allergy Immunotherapy Market revenue, with North America and Europe dominating due to a combination of high healthcare expenditures and robust Research and Development initiatives. The overall market growth is influenced by rising allergy incidences and an emphasis on personalized medicine, highlighting opportunities across all regions for future advancements in allergic disease management.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Allergy Immunotherapy Market Key Players and Competitive Insights

The Allergy Immunotherapy Market is characterized by growing competition as significant developments in the field of immunotherapy, biotechnology, and pharmaceuticals continue to shape the landscape. Several key players have emerged, driving innovation and expanding their product offerings to cater to a rising number of allergy sufferers worldwide. The market is witnessing an increase in strategic collaborations, partnerships, and mergers as companies seek to enhance their portfolio, broaden their geographic reach, and leverage the expertise of others within the industry. The competitive dynamics are further influenced by the growing awareness of allergy and immunotherapy treatments, leading to the introduction of advanced therapy options that improve patient outcomes and provide therapists with more effective solutions.

Novartis has established a prominent position within the Allergy Immunotherapy Market by leveraging its comprehensive portfolio of innovative therapies and a strong global footprint. The company's commitment to research and development has resulted in the introduction of advanced allergy immunotherapy products that address various forms of allergic reactions. A notable strength of Novartis lies in its ability to effectively navigate regulatory landscapes, enabling timely product approvals and market entry in diverse regions. This, combined with robust distribution channels and strategic collaborations, has allowed Novartis to solidify its presence in the allergy immunotherapy space. Their ongoing investment in research and patient engagement initiatives further enhances their standing as a key player in providing meaningful solutions for allergy sufferers worldwide.

Hal Allergie is actively involved in the Allergy Immunotherapy Market, offering a range of immunotherapy solutions designed to address different allergic conditions. Their key products include various allergy vaccines and diagnostic tools that cater to specific allergens, enhancing their market presence. Hal Allergie has built a reputation for delivering high-quality allergen immunotherapy treatments, aided by their commitment to innovation and stringent production standards. Their strength in the market is underscored by a solid distribution network and strategic collaborations that facilitate their growth in global regions. The company has also pursued mergers and acquisitions to expand its product portfolio and capabilities, further positioning itself as a reliable provider in the allergy immunotherapy segment. Through these efforts, Hal Allergie aims to maintain its competitive edge and continue contributing to advancements in allergy treatment globally.

Key Companies in the Allergy Immunotherapy Market Include

• Novartis


• Hal Allergie


• Merck Group


• Lofarma


• Allergopharma GmbH


• AstraZeneca


• Stallergenes Greer


• Aimmune Therapeutics

Allergy Immunotherapy Market Industry Developments

Recent developments in the Allergy Immunotherapy Market have been significant, particularly with advancements in treatment options and company positioning. In October 2023, Aimmune Therapeutics announced promising results from its clinical trials on peanut allergy treatments, further validating the efficacy of immunotherapy. Meanwhile, Novartis has focused on expanding its portfolio in allergy treatments, partnering with several biotech firms to enhance its Research and Development pipeline.

Current affairs also reveal that Merck Group has launched new combination therapies that aim to improve patient outcomes in allergy management. Over the last two years, market valuation has seen a steady increase, attributed to rising allergy prevalence and innovative treatments like sublingual immunotherapy gaining acceptance. The market growth is further fueled by ongoing regulatory support for allergy treatment innovations, indicating a robust future for the Allergy Immunotherapy Market.

Allergy Immunotherapy Market Segmentation Insights

Allergy Immunotherapy Market Type Outlook

• Subcutaneous Immunotherapy


• Sublingual Immunotherapy


• Oral Immunotherapy

Allergy Immunotherapy Market Product Outlook

• Allergen Extracts


• Conventional Immunotherapy


• Biologics

Allergy Immunotherapy Market Indication Outlook

• Allergic Rhinitis


• Allergic Asthma


• Atopic Dermatitis


• Food Allergies

Allergy Immunotherapy Market Patient Type Outlook

• Pediatric


• Adult


• Geriatric

Allergy Immunotherapy Market Regional Outlook

1. North America


2. Europe


3. South America


4. Asia Pacific


5. Middle East and Africa

Report Attribute/Metric	Details
Market Size 2023	5.32(USD Billion)
Market Size 2024	5.71(USD Billion)
Market Size 2035	12.5(USD Billion)
Compound Annual Growth Rate (CAGR)	7.38% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Novartis, Hal Allergie, Merck Group, Lofarma, Allergopharma GmbH, AstraZeneca, Stallergenes Greer, Aimmune Therapeutics
Segments Covered	Type, Product, Indication, Patient Type, Regional
Key Market Opportunities	Personalized treatment development, Increased prevalence of allergies, Growing awareness of immunotherapy, Technological advancements in delivery methods, Expanding market in emerging economies
Key Market Dynamics	Rising allergy prevalence, Increased awareness and diagnosis, Advances in immunotherapy techniques, Growing investment in research, Regulatory support and approval
Countries Covered	North America, Europe, APAC, South America, MEA